{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T19:11:20Z","timestamp":1781032280411,"version":"3.54.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Immunosuppressive agents such as tacrolimus (TAC) and cyclosporin might cause glycemic disorders by suppressing insulin production. However, only a few cases of diabetic ketoacidosis (DKA) with longitudinal evaluation of endogenous insulin secretion related to TAC administration have been reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 59-year-old Asian woman, who received prednisolone and TAC 4.0\u200amg for the treatment of anti-aminoacyl-tRNA synthetase antibody-positive interstitial pneumonia, was admitted to our hospital due to impaired consciousness and general malaise.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>She had metabolic acidosis; her plasma glucose, fasting serum C-peptide immunoreactivity (CPR), and urinary CPR levels were 989\u200amg\/dL (54.9\u200ammol\/L), 0.62\u200ang\/mL, and 13.4\u200a\u03bcg\/d, respectively. No islet-related autoantibodies were detected. Therefore, she was diagnosed with TAC-induced DKA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention:<\/jats:title>\n            <jats:p>Intravenous continuous insulin infusion and rapid saline infusion were administered. TAC was discontinued because of its diabetogenic potential.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Sixteen weeks after cessation of TAC administration, she showed good glycemic control without administration of insulin or any oral hypoglycemic agents; her serum CPR level also improved dramatically. These findings suggested that TAC-induced pancreatic beta cell toxicity is reversible.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>We reported a case of TAC-induced DKA with subsequent recovery of pancreatic beta cell function after cessation of TAC, resulting in good glycemic control. As TAC is widely used, we should pay attention to patients\u2019 glucose levels even though the TAC concentrations used are within the target range. Furthermore, dose reduction or cessation of TAC should be considered if hyperglycemia is detected during administration of this agent.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000016992","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T09:58:08Z","timestamp":1567677488000},"page":"e16992","source":"Crossref","is-referenced-by-count":8,"title":["Tacrolimus-induced diabetic ketoacidosis with subsequent rapid recovery of endogenous insulin secretion after cessation of tacrolimus"],"prefix":"10.1097","volume":"98","author":[{"given":"Koji","family":"Maruyama","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global health and Medicine, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Chujo","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global health and Medicine, Tokyo"},{"name":"Center for Clinical Research, Toyama University Hospital, Toyama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,9]]},"reference":[{"key":"R1-20230914","first-page":"4606491","article-title":"Posttransplant tacrolimus-induced diabetic ketoacidosis: review of the literature","volume":"2018","author":"Ammari","year":"2018","journal-title":"Case Rep Endocrinol"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/00007890-199506000-00018","article-title":"Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell","volume":"59","author":"Tamura","year":"1995","journal-title":"Transplantation"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s12098-012-0797-6","article-title":"Tacrolimus induced diabetic ketoacidosis in nephrotic syndrome","volume":"80","author":"Sarkar","year":"2013","journal-title":"Indian J Pediatr"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/art.21240","article-title":"Treatment of antisynthetase-associated interstitial lung disease with tacrolimus","volume":"52","author":"Wilkes","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"(suppl)","key":"R5-20230914","first-page":"S118","article-title":"Hospital admission guidelines for diabetes mellitus","volume":"26","year":"2003","journal-title":"Diabetes Care"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(89)91014-3","article-title":"FK 506 for liver, kidney, and pancreas transplantation","volume":"2","author":"Starzl","year":"1989","journal-title":"Lancet"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.143.2.718","article-title":"The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes","volume":"143","author":"Tocci","year":"1989","journal-title":"J Immunol"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1124\/mol.63.6.1289","article-title":"Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice","volume":"63","author":"Oetjen","year":"2003","journal-title":"Mol Pharmacol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1172\/JCI119105","article-title":"Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells","volume":"98","author":"Redmon","year":"1996","journal-title":"J Clin Invest"},{"key":"R10-20230914","first-page":"1237","article-title":"Evaluation of treatment status and safety of tacrolimus in patients with interstitial pneumonia complicated with polymyositis or dermatomyositis","volume":"66","author":"Wakasugi","year":"2017","journal-title":"J N Remed Clin"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s00467-006-0102-x","article-title":"Transient insulin-dependent diabetes mellitus in children with steroid-dependent idiopathic nephrotic syndrome during tacrolimus treatment","volume":"21","author":"Dittrich","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0961203310365714","article-title":"Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis","volume":"19","author":"Lanata","year":"2010","journal-title":"Lupus"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data","volume":"331","author":"Webster","year":"2005","journal-title":"BMJ"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2337\/diacare.25.3.583","article-title":"Posttransplantation diabetes: a systematic review of the literature","volume":"25","author":"Montori","year":"2002","journal-title":"Diabetes Care"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1399-5448.2011.00782.x","article-title":"The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus","volume":"13","author":"Prokai","year":"2012","journal-title":"Pediatr Diabetes"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000016992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T21:07:16Z","timestamp":1694725636000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000016992"}},"subtitle":["A case report with review of literature"],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":15,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000016992","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}